Ajulemic acid and efficacy in the treatment of systemic sclerosis

Date Posted: Tuesday, December 04, 2018

Sumner Burstein, PhD, BMP Professor Emeritus
A drug candidate discovered in the Burstein Lab recently entered an FDA-approved Phase 3 clinical trial to demonstrate efficacy in the treatment of systemic sclerosis. Ajulemic acid is a first-in-class agent that resolves chronic inflammation by a mechanism involving the production of lipid signaling molecules that differs from the NSAID class of anti-inflammatory drugs. Systemic sclerosis is an autoimmune disease that progressively reduces lung function and in many cases is fatal. The annual incidence of systemic sclerosis is 19 per million, and its prevalence is 19–75 per 100,000, with a female:male ratio of 3:1. Ajulemic acid has been granted fast track status by The FDA and could become available to patients in 1-2 years depending on the rate of progress in Phase 3.